Picture EBD Group BioTech Showcase 2020 San Francisco BEU2020 650x76px

Document › Details

Apitope International N.V.. (10/31/17). "Press Release: Apitope Announces Its Intention to Launch an Initial Public Offering and Listing on Euronext Brussels [Not for release in US, AU, CA, JP or any other jurisdiction where prohibited by applicable law]

	Region	Brussels
	Country	Belgium
	Organisation	Apitope International N.V.
	Group	Apitope (Group)
	Organisation 2	Euronext Brussels
	Group	Euronext (Group)
	Product	ATX-MS-1467 (Apitope)
	Product 2	investment banking
	Index term	Apitope–SEVERAL: investment, 201710– IPO at Euronext Brussels incl public offering in BE + private placement to qualified investors outside US
	Person	Martin, Keith (Apitope 201810 Non-Executive Director before 2006–201810 CEO RETIRED 10/18)
	Person 2	Clark, Mary (Optimum Strategic Communications 201710 before Hume Brophy + M:Communications + Capital MSL)

Original document
accessed by [iito] on 2017-10-31

Record changed: 2017-11-17

Picture [LSA] Life-Sciences-Asia.com – The Business Web Portal 650x89px

More documents for Apitope (Group)

[1] Apitope International N.V.. (10/24/18). "Press Release: Apitope Announces Management Changes. Keith Martin to Retire as CEO, Continue as Non-Executive Director – Hayley French Appointed COO and Interim CEO". Hasselt & Chepstow....
[2] Apitope International N.V.. (9/29/15). "Press Release: Apitope Raises €12 Million in Series B Funding to Progress Treatments for Autoimmune Diseases. Investment led by Wales Life Sciences Fund". Cardiff & Hasselt....
[3] Apitope International N.V.. (1/8/14). "Press Release: Apitope Led Consortium Receives Up to €6m FP7 Funding to Develop Novel Therapeutic Vaccine for Graves’ Disease". Bristol & Hasselt....
[4] Apitope International N.V.. (9/3/13). "Press Release: Apitope Announces Positive Results from Clinical Trial of ATX-MS-1467 in Relapsing Multiple Sclerosis". Bristol & Hasselt....
[5] Apitope International N.V.. (11/26/12). "Press Release: Apitope Completes Recruitment into Its Clinical Trial of ATX-MS-1467 in Multiple Sclerosis". Hamburg & Bonn....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

» top